A Study on the Improvement of Postoperative Symptoms and Survival Benefits of Modified Bufei Decoction in Elderly Patients With Lung Cancer Undergoing Radical Surgery

ConditionLung Cancers
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age65+
SponsorPeking University Cancer Hospital & Institute

About this trial

This is a randomized double-blind placebo-controlled phase II clinical study that included patients with symptoms such as cough, shortness of breath, and fatigue after lung cancer resection surgery. They were given orally modified Bufei Tang granules twice a day for 28 days, with one packet taken orally with water. Using the MDASI-TCM symptom scoring system, evaluate the scores of symptoms such as cough, shortness of breath, and fatigue before and after the experiment, and calculate the difference in scores between the control group and the experimental group before and after the experiment.

Eligibility criteria

Qualifiers

Patients with postoperative lung cancer who have clear histological or cytological diagnosis.

Age ≥ 65 years old, both male and female are eligible. According to the MDASI-TCM scale evaluation, any of the three symptoms of cough, fatigue, and shortness of breath should score ≥ 4 points, or the sum of the three should score ≥ 6 points.

The heart function is basically normal; ALT/AST is within 2 times the normal value; SCr is within the normal range.

Disqualifiers

Patients with severe pulmonary infections. ⑵. Patients with mental illness. ⑶. Patients with depression.

Trial design

Treatments tested in this trial

  • Jiawei Bufei Tang granules
  • Placebo

Treatment groups

174 Participants
are divided into 2 treatment groups